Search results for Brtx-100

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Imp...

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Imp...

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least…

Spectrum Spine Inc Earns FDA Clearance for Next Generation Nanotechnology – BioBraille™

BioBraille™ is a Precise and Subtractive Surface Nanotechnology Proven to have a Dramatic, Reproducible Biologic Effect on Stimulating…

Spectrum Spine Inc Earns FDA Clearance for Next Generation Nanotechnology – BioBraille™

Bioretec Advances U.S. Commercialization of First-of-Its-Kind Absorbable Metal Implant

MTF Biologics® and Kolosis BIO® Launch the Latest Addition to the DBX Family: DBX® Fiber

Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zen...

LEXINGTON, Mass., April 14, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announces the submission of a supplemental Bio...

Bioretec Ltd’s business review Q1 2026: Early Traction from Renewed Strategy

Bioretec Ltd summaries its 1Q26 revenue and strategy. The post Bioretec Ltd’s business review Q1 2026: Early Traction from Renewed Stra...

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

Allergan Aesthetics Receives Positive CHMP Opinion for TrenibotulinumtoxinE for Glabellar Lines

The botulinum neurotoxin type E candidate is designed for a faster onset and shorter duration of effect than currently available neurotoxin treatments.

Abstract No. LBA18 Blood Quality and Safety of Autologous Blood Return using a Continuous Aspiration Thrombectomy System...

Autologous blood return during PE thrombectomy offers blood conservation benefits, yet comprehensive blood quality validation remains limited. We evaluated the safety and quality o...

MTF Biologics® and Kolosis BIO® Launch the Latest Addition to the DBX Family: DBX® Fiber

DBX portfolio expands with fiber tissue form, processed for addressing complex fusion environments EDISON, N.J. & SALT LAKE…

Abstract No. LBA20 Results from the GPX IDE Pivotal Clinical Trial (Evaluation of a Simple-Prep Controlled Embolic)

Distal embolization is desired for many embolic applications. In an IDE pivotal trial, a novel liquid embolic was used in both durable and pre-operative distal embolization procedu...

MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial...

PainTEQ Launches TRAQв„ў, A Next-Generation Posterior Approach to SI Joint Fusion

ArthroTAK Receives FDA 510(k) Clearance for the ArthroTAKâ„¢ Tendon Anchor Kit, a Sutureless, Soft-Tissue Fixation Syste...

World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Inves...

Abstract No. LBA5 Clinical, functional, and quality of life outcomes through 90 days in the STORM-PE RCT for mechanical...

Pulmonary embolism (PE) treatment with mechanical thrombectomy (MT) can rapidly relieve RV overload and may lead to faster normalization of hemodynamics and functional status compa...

Abstract No. LBA9 A Prospective Multicenter Single-Arm Study to Evaluate the Safety and Effectiveness of Embraceâ„¢ Hydr...

A prospective, single-arm, multicenter study to evaluate the safety and effectiveness of Embrace Hydrogel Embolic System (HES), for transcatheter embolization of peripheral arteria...

Biodynamik Receives FDA IDE Approval for Pivotal U.S. Trial of XT3 System in Diabetic Foot Ulcers

AAN2026 Can Tolebrutinib be revived?

Tolebrutinib which is a irreversible BTK inhibitor was shown in a trial to inhibit non-relapsing progressive MS, but development has been held up in US because of liver damage sign...

Theragen Receives First European Patent for ActaStim®-S

Company’s BGS Is Most Advanced Device in Categoryin More than Two Decades Jacksonville, FL, April 28, 2026 /OrthoSpineNews/…

Atreon and RenovoDerm Put Tendons and Wounds Under One Synthetic Roof

Two rapidly growing synthetic biomaterials platforms, Atreon Orthopedics and RenovoDerm, have merged and the synergies are clear.

Cerapedics Announces Supplier Agreement with Vizient for PearlMatrixВ® P-15 Peptide Enhanced Bone Graft